Posted by Michael Wonder on 08 Dec 2022
Visiox Pharma announces FDA acceptance of new drug application for glaucoma
8 December 2022 - Visiox Pharma today announced that it has received notification from the US FDA that the agency has completed its filing review and accepted for filing the new drug application for PDP-716 (0.35% brimonidine tartrate) for the treatment of glaucoma.
The FDA has assigned a Prescription Drug User Fee Act target action date of 4 August 2023.
